Compare Stocks: HELP, OGN, ARQT, and TARS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$24.33 -3.3%	$25.57	$19.30 ▼ $31.77	$3.06B	1.57	1.78 million shs	697,660 shs
HELP Cybin	$10.87 -4.8%	$11.83	$3.76 ▼ $15.15	$857.84M	0.53	1.25 million shs	940,187 shs
OGN Organon & Co.	$13.75 +0.3%	$13.69	$5.69 ▼ $13.78	$3.61B	1.55	5.28 million shs	484,551 shs
TARS Tarsus Pharmaceuticals	$74.48 +0.0%	$73.36	$53.89 ▼ $91.53	$3.27B	0.44	752,484 shs	131,347 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	-0.04%	-7.98%	+5.23%	-9.11%	+26.26%
HELP Cybin	-2.39%	-9.29%	-6.55%	+89.39%	+1,141,999,900.00%
OGN Organon & Co.	-0.16%	-0.07%	-0.47%	+1.55%	+24.40%
TARS Tarsus Pharmaceuticals	+2.00%	-3.06%	-17.98%	+5.54%	+14.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$24.33 -3.3%	$25.57	$19.30 ▼ $31.77	$3.06B	1.57	1.78 million shs	697,660 shs
HELP Cybin	$10.87 -4.8%	$11.83	$3.76 ▼ $15.15	$857.84M	0.53	1.25 million shs	940,187 shs
OGN Organon & Co.	$13.75 +0.3%	$13.69	$5.69 ▼ $13.78	$3.61B	1.55	5.28 million shs	484,551 shs
TARS Tarsus Pharmaceuticals	$74.48 +0.0%	$73.36	$53.89 ▼ $91.53	$3.27B	0.44	752,484 shs	131,347 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	-0.04%	-7.98%	+5.23%	-9.11%	+26.26%
HELP Cybin	-2.39%	-9.29%	-6.55%	+89.39%	+1,141,999,900.00%
OGN Organon & Co.	-0.16%	-0.07%	-0.47%	+1.55%	+24.40%
TARS Tarsus Pharmaceuticals	+2.00%	-3.06%	-17.98%	+5.54%	+14.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.67	Moderate Buy	$35.57	46.23% Upside
HELP Cybin	3.00	Buy	$46.33	326.33% Upside
OGN Organon & Co.	1.71	Reduce	$11.40	-17.06% Downside
TARS Tarsus Pharmaceuticals	2.80	Moderate Buy	$100.86	35.41% Upside

Current Analyst Ratings Breakdown

Latest HELP, OGN, ARQT, and TARS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
9/24/2026	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$116.00
9/24/2026	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$116.00
9/18/2026	HELP Cybin	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$35.00
9/16/2026	TARS Tarsus Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$110.00
9/16/2026	TARS Tarsus Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$110.00
9/8/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/8/2026	TARS Tarsus Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$88.00 ➝ $105.00
9/4/2026	TARS Tarsus Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$88.00 ➝ $105.00
8/20/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/20/2026	HELP Cybin	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $62.00

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$463.98M	6.59	N/A	N/A	$1.55 per share	15.69
HELP Cybin	N/A	N/A	N/A	N/A	$4.49 per share	N/A
OGN Organon & Co.	$6.22B	0.58	$5.80 per share	2.37	$2.89 per share	4.76
TARS Tarsus Pharmaceuticals	$606.33M	5.39	N/A	N/A	$8.09 per share	9.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$16.14M	$0.21	115.95	21.34	N/A	6.15%	15.05%	6.51%	10/27/2026 (Estimated)
HELP Cybin	-$148M	-$3.02	N/A	N/A	N/A	N/A	-71.78%	-64.81%	N/A
OGN Organon & Co.	$187M	$0.77	17.85	4.00	1.27	3.41%	88.97%	6.03%	11/9/2026 (Estimated)
TARS Tarsus Pharmaceuticals	-$66.42M	-$1.09	N/A	124.14	N/A	-7.67%	-13.53%	-8.12%	11/3/2026 (Estimated)

Latest HELP, OGN, ARQT, and TARS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	TARS Tarsus Pharmaceuticals	-$1.49	N/A	N/A	N/A	$182.74 million	N/A
10/27/2026	Q3 2026	ARQT Arcutis Biotherapeutics	$0.1871	N/A	N/A	N/A	$141.69 million	N/A
8/14/2026	Q1 2027	HELP Cybin	-$0.80	-$0.91	-$0.11	-$0.91	N/A	N/A
8/6/2026	Q2 2026	TARS Tarsus Pharmaceuticals	-$0.1918	-$0.43	-$0.2382	-$0.43	$169.65 million	$173.91 million
8/5/2026	Q2 2026	ARQT Arcutis Biotherapeutics	$0.0551	$0.11	+$0.0549	$0.11	$118.85 million	$129.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
HELP Cybin	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.58%	N/A	10.39%	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest HELP, OGN, ARQT, and TARS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/31/2026	OGN Organon & Co.	quarterly	$0.02	0.58%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.46	2.92	2.67
HELP Cybin	N/A	10.97	10.97
OGN Organon & Co.	8.43	1.95	1.44
TARS Tarsus Pharmaceuticals	0.21	3.20	3.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
HELP Cybin	17.94%
OGN Organon & Co.	77.43%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
HELP Cybin	15.00%
OGN Organon & Co.	1.62%
TARS Tarsus Pharmaceuticals	9.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	354	125.69 million	113.88 million	Optionable
HELP Cybin	100	78.78 million	67.62 million	N/A
OGN Organon & Co.	10,000	262.61 million	258.36 million	Not Optionable
TARS Tarsus Pharmaceuticals	370	43.88 million	39.65 million	Optionable

HELP, OGN, ARQT, and TARS Headlines

Recent News About These Companies

Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options

3 hours ago | seekingalpha.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

October 5 at 2:28 AM | americanbankingnews.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Now Rated "Moderate Buy" by Wall Street Analysts

October 5 at 2:28 AM | marketbeat.com

Head-To-Head Survey: Tarsus Pharmaceuticals (NASDAQ:TARS) & Astrazeneca (NYSE:AZN)

October 4 at 3:58 AM | americanbankingnews.com

Tarsus to Present 11 Abstracts at Anaheim Eye Meeting

September 29, 2026 | ocbj.comO

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry ...

September 29, 2026 | markets.businessinsider.com

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

September 29, 2026 | globenewswire.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to "Strong-Buy" at The Goldman Sachs Group

September 26, 2026 | marketbeat.com

Tarsus Pharmaceuticals (TARS) Receives a Buy from Goldman Sachs

September 25, 2026 | theglobeandmail.com

Bank of America Corp DE Acquires New Stake in Tarsus Pharmaceuticals, Inc. $TARS

September 20, 2026 | marketbeat.com

Tarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC Filing

September 19, 2026 | finance.yahoo.com

Pyott David E I Executes Options in Tarsus Pharmaceuticals, Retains 9,575 Shares

September 18, 2026 | kalkinemedia.comK

Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded by Barclays to Strong-Buy Rating

September 18, 2026 | marketbeat.com

William Phd Link Sells 12,500 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

September 17, 2026 | marketbeat.com

Hsbc Holdings PLC Grows Stake in Tarsus Pharmaceuticals, Inc. $TARS

September 12, 2026 | marketbeat.com

Wellington Management Group LLP Purchases 24,117 Shares of Tarsus Pharmaceuticals, Inc. $TARS

September 11, 2026 | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $905,600.00 in Stock

September 10, 2026 | insidertrades.com

Squarepoint Ops LLC Buys 54,791 Shares of Tarsus Pharmaceuticals, Inc. $TARS

September 10, 2026 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Moderate Buy" from Analysts

September 10, 2026 | marketbeat.com

Bobak Azamian Sells 10,000 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

September 9, 2026 | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $942,637.50 in Stock

September 9, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HELP, OGN, ARQT, and TARS Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$24.33 -0.82 (-3.28%)

As of 12:47 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Cybin NASDAQ:HELP

$10.87 -0.55 (-4.83%)

As of 12:47 PM Eastern

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Organon & Co. NYSE:OGN

$13.74 +0.05 (+0.33%)

As of 12:47 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Tarsus Pharmaceuticals NASDAQ:TARS

$74.48 +0.02 (+0.03%)

As of 12:47 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HELP, OGN, ARQT, and TARS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HELP, OGN, ARQT, and TARS Earnings

Compare Dividends

Latest HELP, OGN, ARQT, and TARS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HELP, OGN, ARQT, and TARS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HELP, OGN, ARQT, and TARS Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

Cybin NASDAQ:HELP

Organon & Co. NYSE:OGN

Tarsus Pharmaceuticals NASDAQ:TARS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools